|
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster Clinical research trials and Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster. Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster clinical trial. Participants frequently obtain the most expert healthcare available for their Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster  Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
For Condition: Immunologic Deficiency Syndromes,Herpes Zoster
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , University of Texas
Synopsis: OBJECTIVES: I. Compare the efficacy and safety of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster. II. Compare quality of life, pain, and medical resource utilization in patients treated with these 2 regimens.
Details: PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are randomized to one of two treatment arms. Arm I: Patients receive standard dose oral valacyclovir three times a day on Days 1-7. Arm II: Patients receive higher dose oral valacyclovir three times a day on Days 1-7. Both arms: Patients begin treatment within 72 hours after onset of zoster rash. Quality of life is assessed on Days 1, 14, and 28 during study and then every 4 weeks through Week 24. Pain is assessed on Days 1-28 during study, and then weekly through Week 24. Medical resource utilization is assessed on Days 1, 8, 14, and 18 during study and then every 4 weeks through Week 24. Patients are followed every 4 weeks through Week 24.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Patients with a clinical diagnosis of uncomplicated herpes zoster presenting within 72 hours after onset of zoster rash No evidence of cutaneous or visceral dissemination of herpes zoster infection; cutaneous dissemination defined as at least 20 discrete lesions outside adjacent dermatomes Must have immune dysfunction caused by any of the following: congenital immune deficiency; active malignancy of any type; collagen vascular diseases; organ or bone marrow transplantation; HIV infection; severe atopic dermatitis; received cytotoxic drugs or immunosuppressive therapy (e.g., chronic systemic corticosteroids) within past 3 months CD4 count at least 50% --Prior/Concurrent Therapy-- Biologic therapy: Greater than 9 months since prior bone marrow transplantation Surgery: Greater than 9 months since prior liver or heart transplantation Other: At least 4 weeks since prior topical or systemic anti-varicella zoster virus (anti-VZV) medications; no concurrent systemic agents with anti-VZV activity from enrollment to Day 10; no concurrent probenecid from 24 hours before the first dose of study drug until Day 10 --Patient Characteristics-- Hepatic: AST or ALT no greater than 5 times upper limit of normal Renal: Creatinine clearance at least 30 mL/min Other: Not pregnant or nursing; negative pregnancy test; fertile patients must use effective contraception; no history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, or famciclovir
Total Enrollment: 66
Location and Contact Information:
Overall Study Official:
StephenTyring, Study Chair, University of Texas
University of Texas Medical Branch *Recruiting*
Galveston, Texas, 77555-0209
United States
Recruiting Stephen Tyring 281-333-2288
Additional Information:
Study ID Numbers: 199/15324; UTMB-GCRC-D085,UTMB-97-120,GW-R-24
Study Start Date: January 1997
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006131
Other Herpes Zoster Studies:
1. Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
2. Pilot Study of Allogeneic Bone Marrow Transplantation Plus Cyclosporine and Mycophenolate Mofetil to Induce Mixed Hematopoietic Chimerism in Patients With Primary T-Cell Immunodeficiency Disorders
3. Studies of the Immune Response in Normal Subjects and Patients with Disorders of the Immune System
4. Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
5. Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
Related Studies:
Other Herpes Zoster Clinical Trials
Other Texas Clinical Trials
Other Galveston Clinical Trials
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
|
|
|
|
|
|
|
|
